Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid pain medicines. Their lead product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors designed to inhibit pain transmission. The company aims to address the unmet need for effective, non-addictive pain relief alternatives to opioids.